Skyhawk's SKY-0515 Shows Disease Stabilization in Huntington's Trial — Skyhawk Therapeutics, Inc.

Event summary

Skyhawk Therapeutics released 12-month data from its Phase 1/2 trial of SKY-0515, showing stabilization or improvement in all cUHDRS subcomponents for Huntington's disease patients.
Participants on SKY-0515 demonstrated favorable changes across TFC (+0.07), TMS (-2.00), SDMT (-0.19), and SWRT (+3.44) compared to expected worsening from natural history datasets.
65% of patients and 50% of clinicians reported disease improvement, with no participants showing progression after 12 months.
SKY-0515 achieved up to 69% reduction in mutant huntingtin protein and 26% reduction in PMS1 mRNA.

The big picture

Skyhawk's data suggests SKY-0515 could be the first disease-modifying therapy for Huntington's, a fatal neurodegenerative disorder with no approved treatments. The results position Skyhawk as a key player in RNA-targeting therapies, though competition and regulatory hurdles remain. With over 40,000 symptomatic patients in the U.S. alone, success could represent a significant commercial opportunity.

What we're watching

Clinical Validation: Whether the Phase 2/3 FALCON-HD trial will confirm these results in a larger, placebo-controlled setting.
Regulatory Pathway: The pace at which Skyhawk can advance SKY-0515 toward potential approval given the unmet need in Huntington's disease.
Pipeline Expansion: How quickly Skyhawk can translate its SKYSTAR platform into additional clinical programs by late 2027.